Go Pro
NASDAQ:CHGA

Avalon GloboCare Q2 2025 Earnings Report

Avalon GloboCare logo
$2.07 +0.03 (+1.47%)
As of 09/18/2026 04:00 PM Eastern

Avalon GloboCare EPS Results

Actual EPS
-$40.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Avalon GloboCare Revenue Results

Actual Revenue
$0.35 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Avalon GloboCare Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
8:00AM ET

Earnings Documents

Avalon GloboCare Earnings Headlines

Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.tc pixel
Change Agents Announces 1-for-20 Reverse Stock Split
See More Avalon GloboCare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avalon GloboCare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalon GloboCare and other key companies, straight to your email.

About Avalon GloboCare

Avalon GloboCare (NASDAQ:CHGA) is a life sciences company focused on developing cell-based technologies and precision medicine applications. Its work has included regenerative medicine, cancer diagnostics, and therapeutic platforms designed to support the development of personalized healthcare treatments.

The company has also pursued technologies involving cellular processing, biomanufacturing, and related laboratory services. Avalon GloboCare’s activities have included collaborations and development programs intended to translate emerging cell and molecular science into clinical and commercial applications.

Avalon GloboCare was established in the mid-2010s and has been headquartered in Freehold, New Jersey. Public company materials have identified David Jin as a senior executive and have described the company as serving the biotechnology and healthcare markets, although specific programs, operations, and leadership arrangements may change over time.

View Avalon GloboCare Profile